BFC Planning’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TGTX
BFC Planning's TGTX Position: Q3 2026 in Review
BFC Planning increased its TG Therapeutics (TGTX) stake by 3.8% in Q3 2026, buying an estimated $704 and bringing the position to 351 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2046.
BFC Planning first reported a position in TGTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $23.3K in Q1 2025. 376 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.
- BFC Planning held 351 shares of TG Therapeutics worth $19.6K as of Q3 2026.
- BFC Planning bought 13 TG Therapeutics shares in Q3 2026, an estimated $704.
- TG Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2046 holding.
- BFC Planning first reported a position in TG Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's TG Therapeutics position peaked at $23.3K in Q1 2025.
- 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.